Novel chewing gum formulation helps prevent motion sickness

A new prototype for medicated chewing gum has been developed for motion sickness that may offer many advantages over conventional oral solid dosage forms. About 33 percent of people are susceptible to motion sickness in mild circumstances and 66 percent are affected in more severe conditions. This research is being presented at the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in Chicago, Ill., Oct. 14 – 18, an international event anticipating more than 8,000 attendees.

Lead researcher Mohsen Sadatrezaei of RoshaDarou Co. and a team of researchers consisting of Niloufar Pouyan, Zoherh JafariAzar and Alireza Ghaffari from the Islamic Azad University School of (Tehran, Iran), have developed a medicated gum that will improve patient compliance and faster absorption through the cheek, which will alleviate sooner. A sensory panel was used to test faster absorption through the buccal cavity, which will result in earlier onset of action against motion sickness. Panelists also ranked the gum on bitterness and easiness to chew.

"The main challenge in delivering drugs through chewing gum is masking the bitter taste of its active ingredient," said Sadatrezaei. "We have formulated dimenhydrinate as chewing gum with acceptable taste and sensory attributes. Dimenhydrinate is among the best for treatment of motion sickness, providing a comfortable and acceptable drug delivery."

The final formulation has great potential for dimenhydrinate chewing gum commercialization. Moreover, the outcome of the study can be used as a platform to incorporate other active ingredients with objectionable taste into .

add to favorites email to friend print save as pdf

Related Stories

Chewing gum -- the new post-operative medicine

Feb 27, 2008

In an article recently recommended by Bradley Kropp of Faculty of 1000 Medicine, researchers find chewing gum is a simple solution to the recovery of bowel function after gastrointestinal surgery – a problem that has troubled ...

Spin-out company gets approval for new nicotine gum

Jul 14, 2011

A new generation of nicotine gum, developed by the University of Bristol spin-out company Revolymer® Ltd, has been given approval for sale in Canada. The gum uses new technology to mask the nicotine taste.

Recommended for you

Mirabegron for overactive bladder: Added benefit not proven

5 hours ago

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

User comments